Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

A. H. Groll, B. M. Gullick, R. Petraitiene, V. Petraitis, M. Candelario, S. C. Piscitelli, T. J. Walsh

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups of three healthy rabbits after single and multiple daily intravenous administration of doses of 1, 3, and 6 mg/kg of body weight. Concentrations were measured by a validated high-performance liquid chromatography method and fitted into a three-compartment open pharmacokinetic model. Across the investigated dosage range, caspofungin displayed dose-independent pharmacokinetics. Following administration over 7 days, the mean peak concentration in plasma (Cmax) ± standard error of the mean increased from 16.01 ± 0.61 μg/ml at the 1-mg/kg dose to 105.52 ± 8.92 μg/ml at the 6-mg/kg dose; the mean area under the curve from 0 h to infinity rose from 13.15 ± 2.37 to 158.43 ± 15.58 μg · h/ml, respectively. The mean apparent volume of distribution at steady state (Vdss) was 0.299 ± 0.011 liter/kg at the 1-mg/kg dose and 0.351 ± 0.016 liter/kg at the 6-mg/kg dose (not significant [NS]). Clearance (CL) ranged from 0.086 ± 0.017 liter/kg/h at the 1-mg/kg dose to 0.043 ± 0.004 liter/kg/h at the 6-mg/kg dose (NS), and the mean terminal half-life was between 30 and 34 h (NS). Except for a trend towards an increased Vdss, there were no significant differences in pharmacokinetic parameters in comparison to those after single-dose administration. Caspofungin was well tolerated, displayed linear pharmacokinetics that fit into a three-compartment pharmacokinetic model, and achieved sustained concentrations in plasma that were multiple times in excess of reported MICs for susceptible opportunistic fungi.

Original languageEnglish (US)
Pages (from-to)596-600
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

caspofungin
Echinocandins
Pharmacokinetics
Rabbits
Lipopeptides
Intravenous Administration
Area Under Curve
Half-Life
Fungi
High Pressure Liquid Chromatography
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Groll, A. H., Gullick, B. M., Petraitiene, R., Petraitis, V., Candelario, M., Piscitelli, S. C., & Walsh, T. J. (2001). Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrobial Agents and Chemotherapy, 45(2), 596-600. https://doi.org/10.1128/AAC.45.2.596-600.2001

Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. / Groll, A. H.; Gullick, B. M.; Petraitiene, R.; Petraitis, V.; Candelario, M.; Piscitelli, S. C.; Walsh, T. J.

In: Antimicrobial Agents and Chemotherapy, Vol. 45, No. 2, 2001, p. 596-600.

Research output: Contribution to journalArticle

Groll, AH, Gullick, BM, Petraitiene, R, Petraitis, V, Candelario, M, Piscitelli, SC & Walsh, TJ 2001, 'Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits', Antimicrobial Agents and Chemotherapy, vol. 45, no. 2, pp. 596-600. https://doi.org/10.1128/AAC.45.2.596-600.2001
Groll, A. H. ; Gullick, B. M. ; Petraitiene, R. ; Petraitis, V. ; Candelario, M. ; Piscitelli, S. C. ; Walsh, T. J. / Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. In: Antimicrobial Agents and Chemotherapy. 2001 ; Vol. 45, No. 2. pp. 596-600.
@article{46ac1b32214b4a17a2074c5496f526e0,
title = "Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits",
abstract = "The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups of three healthy rabbits after single and multiple daily intravenous administration of doses of 1, 3, and 6 mg/kg of body weight. Concentrations were measured by a validated high-performance liquid chromatography method and fitted into a three-compartment open pharmacokinetic model. Across the investigated dosage range, caspofungin displayed dose-independent pharmacokinetics. Following administration over 7 days, the mean peak concentration in plasma (Cmax) ± standard error of the mean increased from 16.01 ± 0.61 μg/ml at the 1-mg/kg dose to 105.52 ± 8.92 μg/ml at the 6-mg/kg dose; the mean area under the curve from 0 h to infinity rose from 13.15 ± 2.37 to 158.43 ± 15.58 μg · h/ml, respectively. The mean apparent volume of distribution at steady state (Vdss) was 0.299 ± 0.011 liter/kg at the 1-mg/kg dose and 0.351 ± 0.016 liter/kg at the 6-mg/kg dose (not significant [NS]). Clearance (CL) ranged from 0.086 ± 0.017 liter/kg/h at the 1-mg/kg dose to 0.043 ± 0.004 liter/kg/h at the 6-mg/kg dose (NS), and the mean terminal half-life was between 30 and 34 h (NS). Except for a trend towards an increased Vdss, there were no significant differences in pharmacokinetic parameters in comparison to those after single-dose administration. Caspofungin was well tolerated, displayed linear pharmacokinetics that fit into a three-compartment pharmacokinetic model, and achieved sustained concentrations in plasma that were multiple times in excess of reported MICs for susceptible opportunistic fungi.",
author = "Groll, {A. H.} and Gullick, {B. M.} and R. Petraitiene and V. Petraitis and M. Candelario and Piscitelli, {S. C.} and Walsh, {T. J.}",
year = "2001",
doi = "10.1128/AAC.45.2.596-600.2001",
language = "English (US)",
volume = "45",
pages = "596--600",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

AU - Groll, A. H.

AU - Gullick, B. M.

AU - Petraitiene, R.

AU - Petraitis, V.

AU - Candelario, M.

AU - Piscitelli, S. C.

AU - Walsh, T. J.

PY - 2001

Y1 - 2001

N2 - The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups of three healthy rabbits after single and multiple daily intravenous administration of doses of 1, 3, and 6 mg/kg of body weight. Concentrations were measured by a validated high-performance liquid chromatography method and fitted into a three-compartment open pharmacokinetic model. Across the investigated dosage range, caspofungin displayed dose-independent pharmacokinetics. Following administration over 7 days, the mean peak concentration in plasma (Cmax) ± standard error of the mean increased from 16.01 ± 0.61 μg/ml at the 1-mg/kg dose to 105.52 ± 8.92 μg/ml at the 6-mg/kg dose; the mean area under the curve from 0 h to infinity rose from 13.15 ± 2.37 to 158.43 ± 15.58 μg · h/ml, respectively. The mean apparent volume of distribution at steady state (Vdss) was 0.299 ± 0.011 liter/kg at the 1-mg/kg dose and 0.351 ± 0.016 liter/kg at the 6-mg/kg dose (not significant [NS]). Clearance (CL) ranged from 0.086 ± 0.017 liter/kg/h at the 1-mg/kg dose to 0.043 ± 0.004 liter/kg/h at the 6-mg/kg dose (NS), and the mean terminal half-life was between 30 and 34 h (NS). Except for a trend towards an increased Vdss, there were no significant differences in pharmacokinetic parameters in comparison to those after single-dose administration. Caspofungin was well tolerated, displayed linear pharmacokinetics that fit into a three-compartment pharmacokinetic model, and achieved sustained concentrations in plasma that were multiple times in excess of reported MICs for susceptible opportunistic fungi.

AB - The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups of three healthy rabbits after single and multiple daily intravenous administration of doses of 1, 3, and 6 mg/kg of body weight. Concentrations were measured by a validated high-performance liquid chromatography method and fitted into a three-compartment open pharmacokinetic model. Across the investigated dosage range, caspofungin displayed dose-independent pharmacokinetics. Following administration over 7 days, the mean peak concentration in plasma (Cmax) ± standard error of the mean increased from 16.01 ± 0.61 μg/ml at the 1-mg/kg dose to 105.52 ± 8.92 μg/ml at the 6-mg/kg dose; the mean area under the curve from 0 h to infinity rose from 13.15 ± 2.37 to 158.43 ± 15.58 μg · h/ml, respectively. The mean apparent volume of distribution at steady state (Vdss) was 0.299 ± 0.011 liter/kg at the 1-mg/kg dose and 0.351 ± 0.016 liter/kg at the 6-mg/kg dose (not significant [NS]). Clearance (CL) ranged from 0.086 ± 0.017 liter/kg/h at the 1-mg/kg dose to 0.043 ± 0.004 liter/kg/h at the 6-mg/kg dose (NS), and the mean terminal half-life was between 30 and 34 h (NS). Except for a trend towards an increased Vdss, there were no significant differences in pharmacokinetic parameters in comparison to those after single-dose administration. Caspofungin was well tolerated, displayed linear pharmacokinetics that fit into a three-compartment pharmacokinetic model, and achieved sustained concentrations in plasma that were multiple times in excess of reported MICs for susceptible opportunistic fungi.

UR - http://www.scopus.com/inward/record.url?scp=0035144963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035144963&partnerID=8YFLogxK

U2 - 10.1128/AAC.45.2.596-600.2001

DO - 10.1128/AAC.45.2.596-600.2001

M3 - Article

C2 - 11158761

AN - SCOPUS:0035144963

VL - 45

SP - 596

EP - 600

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -